Adamax

Adamax

Adamax is a research-grade synthetic nootropic peptide developed for preclinical investigation of cognitive enhancement, neuroprotection, and neurotrophic signalling. Structurally derived from the ACTH(4-7) sequence, Adamax has been studied in experimental models for its ability to modulate brain-derived neurotrophic factor (BDNF) expression, support neuronal survival, and enhance learning and memory consolidation. It represents a distinct compound in the neuropeptide research space, with a well-characterised mechanism and a growing body of preclinical literature.

Mechanism of Action

Adamax exerts its effects primarily through upregulation of BDNF and nerve growth factor (NGF) in the central nervous system, supporting synaptic plasticity and neuronal resilience. It has been shown to modulate serotonergic and dopaminergic neurotransmission in preclinical models, contributing to its observed effects on mood, cognition, and stress response. Unlike anxiolytic compounds that act via GABAergic sedation, Adamax demonstrates cognitive-enhancing properties without sedative side effects in research settings, making it a subject of interest for studies on non-sedating neuroprotection.

Research Applications

• Cognitive function, learning, and memory consolidation studies
• BDNF and NGF expression and neurotrophin signalling research
• Neuroprotection and neuronal survival investigation
• Serotonergic and dopaminergic neurotransmission modelling
• Stress response and anxiety biology research

Specifications

• Molecular Formula: C₅₀H₆₉N₁₁O₁₁S
• CAS Number: 80714-61-0
• Purity: ≥98%
• Molecular Weight: 1032.23 g/mol
• Form: Lyophilised powder
• Storage: -20°C
• Shelf Life: 24 months

This product is intended for legitimate laboratory and analytical research use only. Not for diagnostic, therapeutic, or consumer use.